Goldman Sachs Initiates Coverage On Versigent with Buy Rating, Announces Price Target of $48

Benzinga Newsdesk www.benzinga.com Neutral 75.4%

Neg 0% Neu 75.4% Pos 0%

Goldman Sachs analyst Mark Delaney initiates coverage on Versigent (NYSE:VGNT) with a Buy rating and announces Price Target of $48.